

Elena Cela de Julián

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/126769/publications.pdf>

Version: 2024-02-01

24
papers

357
citations

1307594

7
h-index

839539

18
g-index

29
all docs

29
docs citations

29
times ranked

549
citing authors

#	ARTICLE	IF	CITATIONS
1	Newborn screening for sickle cell disease in Europe: recommendations from a Pan-European Consensus Conference. <i>British Journal of Haematology</i> , 2018, 183, 648-660.	2.5	100
2	COVID-19 infection in children and adolescents with cancer in Madrid. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28397.	1.5	99
3	National registry of hemoglobinopathies in Spain (REPHem). <i>Pediatric Blood and Cancer</i> , 2017, 64, e26322.	1.5	39
4	Effect of Poloxamer 188 vs Placebo on Painful Vaso-Occlusive Episodes in Children and Adults With Sickle Cell Disease. <i>JAMA - Journal of the American Medical Association</i> , 2021, 325, 1513.	7.4	24
5	Newborn Screening for Sickle Cell Disease in Europe. <i>International Journal of Neonatal Screening</i> , 2019, 5, 15.	3.2	17
6	Actualización del registro español de hemoglobinopatías de niños y adultos. <i>Medicina Clínica</i> , 2020, 155, 95-103.	0.6	10
7	Cost-effectiveness analysis of newborn screening for sickle-cell disease in Spain. <i>Expert Opinion on Orphan Drugs</i> , 2016, 4, 567-575.	0.8	9
8	Lactate Dehydrogenase: A Marker of the Severity of Vaso-Occlusive Crisis in Children with Sickle Cell Disease Presenting at the Emergency Department. <i>Hemoglobin</i> , 2016, 40, 388-391.	0.8	8
9	Low-risk factors for severe bacterial infection and acute chest syndrome in children with sickle cell disease. <i>Pediatric Blood and Cancer</i> , 2019, 66, e27667.	1.5	7
10	Fifteen years of newborn sickle cell disease screening in Madrid, Spain: an emerging disease in a European country. <i>Annals of Hematology</i> , 2020, 99, 1465-1474.	1.8	7
11	Matched sibling donor stem cell transplantation for sickle cell disease: Results from the Spanish group for bone marrow transplantation in children. <i>European Journal of Haematology</i> , 2021, 106, 408-416.	2.2	6
12	Interleukin 6 as a marker of severe bacterial infection in children with sickle cell disease and fever: a case-control study. <i>BMC Infectious Diseases</i> , 2021, 21, 741.	2.9	6
13	Hb M-Saskatoon: An unusual cause of cyanosis in a Spanish child. <i>Pediatric Hematology Oncology Journal</i> , 2019, 4, 23-26.	0.1	5
14	Complications of Central Venous Access Devices in Patients With Sickle Cell Disease and Thalassemia Major. <i>Journal of Pediatric Hematology/Oncology</i> , 2021, 43, e655-e660.	0.6	4
15	Chronic brain damage in sickle cell disease and its relation with quality of life. <i>Medicina Clínica (English Edition)</i> , 2016, 147, 531-536.	0.2	2
16	Lesión crónica cerebral en la anemia falciforme y su relación con la calidad de vida. <i>Medicina Clínica</i> , 2016, 147, 531-536.	0.6	2
17	Editorial for Special Issue "Newborn Screening for Sickle Cell Disease and other Haemoglobinopathies". <i>International Journal of Neonatal Screening</i> , 2019, 5, 36.	3.2	2
18	Update of the Spanish registry of haemoglobinopathies in children and adults. <i>Medicina Clínica (English Edition)</i> , 2020, 155, 95-103.	0.2	1

#	ARTICLE	IF	CITATIONS
19	Evaluation of the effectiveness of prophylactic oral vitamin D (cholecalciferol) in children with sickle cell disease. <i>Bone</i> , 2020, 133, 115228.	2.9	1
20	Pharmacokinetics and safety of ticagrelor in infants and toddlers with sickle cell disease aged <24 months. <i>Pediatric Blood and Cancer</i> , 2021, 68, e28977.	1.5	1
21	Overlap between angiolymphoid hyperplasia with eosinophilia and Kimura's disease in a child with immune thrombocytopenic purpura. <i>Indian Journal of Dermatology</i> , 2019, 64, 159.	0.3	1
22	Risk-score based strategy to minimize antibiotic exposure in children with sickle cell disease and fever. <i>Infection</i> , 2022, 50, 499-505.	4.7	0
23	Pharmacokinetics of Ticagrelor in Infants and Toddlers Aged <24 Months with Sickle Cell Disease. <i>Blood</i> , 2019, 134, 1005-1005.	1.4	0
24	Complete RH and Kell matching related to low alloimmunisation risk in sickle cell disease: prevalence and risk factors of alloimmunisation in a Spanish Tertiary Care National Reference Centre. <i>Blood Transfusion</i> , 2021, 19, 292-299.	0.4	0